Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $6.02 million. The enterprise value is -$4.63 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 3.60 million shares outstanding. The number of shares has increased by 31.55% in one year.
| Current Share Class | 3.60M |
| Shares Outstanding | 3.60M |
| Shares Change (YoY) | +31.55% |
| Shares Change (QoQ) | +49.14% |
| Owned by Insiders (%) | 2.86% |
| Owned by Institutions (%) | 6.90% |
| Float | 3.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.66 |
| Forward PS | 8.72 |
| PB Ratio | 0.17 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.87 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -125.89% and return on invested capital (ROIC) is -157.06%.
| Return on Equity (ROE) | -125.89% |
| Return on Assets (ROA) | -44.28% |
| Return on Invested Capital (ROIC) | -157.06% |
| Return on Capital Employed (ROCE) | -147.54% |
| Weighted Average Cost of Capital (WACC) | 10.04% |
| Revenue Per Employee | $5,413 |
| Profits Per Employee | -$407,791 |
| Employee Count | 115 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.22 |
Taxes
| Income Tax | -1.62M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.98% in the last 52 weeks. The beta is 1.43, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -83.98% |
| 50-Day Moving Average | 2.15 |
| 200-Day Moving Average | 7.35 |
| Relative Strength Index (RSI) | 45.41 |
| Average Volume (20 Days) | 507,276 |
Short Selling Information
The latest short interest is 168,619, so 4.68% of the outstanding shares have been sold short.
| Short Interest | 168,619 |
| Short Previous Month | 57,017 |
| Short % of Shares Out | 4.68% |
| Short % of Float | 4.82% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $622,489 and -$46.90 million in losses. Loss per share was -$35.25.
| Revenue | 622,489 |
| Gross Profit | 400,112 |
| Operating Income | -31.28M |
| Pretax Income | -48.51M |
| Net Income | -46.90M |
| EBITDA | -30.18M |
| EBIT | -31.28M |
| Loss Per Share | -$35.25 |
Full Income StatementBalance Sheet
The company has $11.88 million in cash and $1.24 million in debt, with a net cash position of $10.65 million or $2.96 per share.
| Cash & Cash Equivalents | 11.88M |
| Total Debt | 1.24M |
| Net Cash | 10.65M |
| Net Cash Per Share | $2.96 |
| Equity (Book Value) | 20.63M |
| Book Value Per Share | 9.85 |
| Working Capital | 10.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.14 million and capital expenditures -$700,047, giving a free cash flow of -$29.84 million.
| Operating Cash Flow | -29.14M |
| Capital Expenditures | -700,047 |
| Depreciation & Amortization | 1.11M |
| Net Borrowing | n/a |
| Free Cash Flow | -29.84M |
| FCF Per Share | -$8.28 |
Full Cash Flow StatementMargins
| Gross Margin | 64.28% |
| Operating Margin | -5,025.53% |
| Pretax Margin | -7,793.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.55% |
| Shareholder Yield | -31.55% |
| Earnings Yield | -779.51% |
| FCF Yield | -495.95% |
Analyst Forecast
The average price target for Co-Diagnostics is $90.00, which is 5,289.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $90.00 |
| Price Target Difference | 5,289.22% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 222.03% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Co-Diagnostics has an Altman Z-Score of -5.9 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.9 |
| Piotroski F-Score | 1 |
